Aptorum Group Announces Dosing First Human Subject In A Phase I Clinical Trial Of ALS-4, A First-In-Class Small Molecule Drug Designed To Treat Infections Caused By Staphylococcus Aureus Including Methicillin-resistant Staphylococcus Aureus